Richard Greil

Richard Greil

Auto-generated profile, based on publicly available information

Richard Greil

Paracelsus Medical University Salzburg, Salzburg, Austria

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LPLisa Pleyer
Lisa Pleyer
HDHartmut Döhner
Hartmut Döhner
HDHervé Dombret
Hervé Dombret
JSJohn Seymour
John Seymour
Andre C. SchuhAndre C. Schuh
Andre C. Schuh
RGRichard Greil
Richard Greil
We recently published a clinically-meaningful improvement in median overall survival (OS) for patients with acute myeloid leukaemia (AML), >30% bone marrow (BM) blasts and white blood cell (WBC) count ≤15 G/L, treated with front-line azacitidine versus conventional care regimens within a phase 3 clinical trial (AZA-AML-001; NCT01074047; registered: February 2010). As results obtained in clinical trials are facing increased pressure to be confirmed by real-world data, we aimed to test whether data obtained in the AZA-AML-001 trial accurately represent observations made in routine clinical practice by analysing additional AML patients treated with azacitidine front-line within the Austrian Azacitidine Registry (AAR; NCT01595295; registered: May 2012) and directly comparing patient-level data of both cohorts. We assessed the efficacy of front-line azacitidine in a total of 407 patients with newly-diagnosed AML. Firstly, we compared data from AML patients with WBC ≤ 15 G/L and >30% BM blasts included within the AZA-AML-001 trial treated with azacitidine (“AML-001” cohort; n = 214) with AAR patients meeting the same inclusion criteria (“AAR (001-like)” cohort; n = 95). The current analysis thus represents a new sub-analysis of the AML-001 trial, which is directly compared with a new sub-analysis of the AAR. Baseline characteristics, azacitidine application, response rates and OS were comparable between all patient cohorts within the trial or registry setting. Median OS was 9.9 versus 10.8 months (p = 0.616) for “AML-001” versus “AAR (001-like)” cohorts, respectively. Secondly, we pooled data from both cohorts (n = 309) and assessed the outcome. Median OS of the pooled cohorts was 10.3 (95% confidence interval: 8.7, 12.6) months, and the one-year survival rate was 45.8%. Thirdly, we compared data from AAR patients meeting AZA-AML-001 trial inclusion criteria (n = 95) versus all AAR patients with World Health Organization (WHO)-defined AML (“AAR (WHO-AML)” cohort; n = 193). Within the registry population, median OS for AAR patients meeting trial inclusion criteria versus all WHO-AML patients was 10.8 versus 11.8 months (p = 0.599), respectively. We thus tested and confirmed the efficacy of azacitidine as a front-line agent in patients with AML, >30% BM blasts and WBC ≤ 15 G/L in a routine clinical practice setting. We further show that the efficacy of azacitidine does not appear to be limited to AML patients who meet stringent clinical trial inclusion criteria, but instead appears efficacious as front-line treatment in all patients with WHO-AML.

16 April 2016 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
LPLisa Pleyer
Lisa Pleyer
SBSonja Burgstaller
Sonja Burgstaller
RSReinhard Stauder
Reinhard Stauder
MGMichael Girschikofsky
Michael Girschikofsky
Heinz SillHeinz Sill
Heinz Sill
RGRichard Greil
Richard Greil
The MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus allowing patients with 20–30 % bone marrow blasts (AML20–30, formerly MDS-RAEB-t) to be categorised and treated as either MDS or AML. In addition, an artificial distinction between AML20–30 and AML30+ was made by regulatory agencies by initially restricting approval of azacitidine to AML20–30. Thus, uncertainty prevails regarding the diagnosis, prognosis and optimal treatment timing and strategy for patients with AML20–30. Here, we aim to provide clarification for patients treated with azacitidine front-line. The Austrian Azacitidine Registry is a multicentre database (ClinicalTrials.gov: NCT01595295). For this analysis, we selected 339 patients treated with azacitidine front-line. According to the WHO classification 53, 96 and 190 patients had MDS-RAEB-I, MDS-RAEB-II and AML (AML20–30: n = 79; AML30+: n = 111), respectively. According to the FAB classification, 131, 101 and 111 patients had MDS-RAEB, MDS-RAEB-t and AML, respectively. The median ages of patients with MDS and AML were 72 (range 37–87) and 77 (range 23–93) years, respectively. Overall, 80 % of classifiable patients (≤30 % bone marrow blasts) had intermediate-2 or high-risk IPSS scores. Most other baseline, treatment and response characteristics were similar between patients diagnosed with MDS or AML. WHO-classified patients with AML20–30 had significantly worse OS than patients with MDS-RAEB-II (13.1 vs 18.9 months; p = 0.010), but similar OS to patients with AML30+ (10.9 vs 13.1 months; p = 0.238). AML patients that showed MDS-related features did not have worse outcomes compared with patients who did not (13.2 vs 8.9 months; p = 0.104). FAB-classified patients with MDS-RAEB-t had similar survival to patients with AML30+ (12.8 vs 10.9 months; p = 0.376), but significantly worse OS than patients with MDS-RAEB (10.9 vs 24.4 months; p < 0.001). Our data demonstrate the validity of the WHO classification of MDS and AML, and its superiority over the former FAB classification, for patients treated with azacitidine front-line. Neither bone marrow blast count nor presence of MDS-related features had an adverse prognostic impact on survival. Patients with AML20–30 should therefore be regarded as having ‘true AML’ and in our opinion treatment should be initiated without delay.

1 March 2011 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
SRSigrun Ressler
Sigrun Ressler
BMBrigitte Mlineritsch
Brigitte Mlineritsch
RGRichard Greil
Richard Greil
Zoledronic acid, a nitrogen-containing bisphosphonate, is firmly established in the management of metastatic bone disease. It inhibits farnesyl diphosphonate synthase within the mevalonate pathway and, through this mechanism, is a potent inhibitor of osteoclast-mediated bone resorption. In addition, there are preclinical data suggesting that farnesyl diphosphonate synthase inhibition by zoledronic acid has anti-tumor effects in breast cancer. Adjuvant therapies for early breast cancer are associated with substantial decreases in bone mineral density. Results from three clinical trials, ABCSG-12, Z-FAST and ZO-FAST, indicate that the addition of twice-yearly zoledronic acid to standard adjuvant endocrine therapy in premenopausal and postmenopausal patients with hormone receptor-positive breast cancer prevents cancer treatment-induced bone loss. Moreover, it is becoming evident that it may also exert anticancer effects in an estrogen-deprived state in the adjuvant and neoadjuvant setting. However, long-term side effects need to be taken into consideration for treatment decisions.

1 November 2014
Verified
Journal Article
Closed access
WEWolfgang Eisterer
Wolfgang Eisterer
AVAlexander De Vries
Alexander De Vries
DÖDietmar Öfner
Dietmar Öfner
HRHans Rabl
Hans Rabl
RKRenate Koplmüller
Renate Koplmüller
JTJosef Thaler
Josef Thaler

31 March 2011 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
CTChristoph Tausch
Christoph Tausch
GSGunther G. Steger
Gunther G. Steger
AHAnton Haid
Anton Haid
RJRaimund Jakesz
Raimund Jakesz
MFMichael A. Fridrik
Michael A. Fridrik
RGRichard Greil
Richard Greil
Over the past years, experience has been increasing with lymphatic mapping and sentinel node biopsy (SNB) after preoperative chemotherapy for breast cancer, with a wide range of results reported in the literature and final conclusions on the diagnostic value and clinical consequences of this sequential approach still missing. Between 1999 and 2002, the Austrian Breast and Colorectal Cancer Study Group (ABCSG) conducted a prospective randomized multicenter trial comparing three versus six preoperative cycles of epirubicin/docetaxel + granulocyte colony-stimulating factor for operable breast cancer. Of the 292 patients recruited to the trial overall, 111 were enrolled in a prospective subprotocol for performing LM and SNB in addition to obligatory axillary lymph node dissection (ALND) after PC. SNB after PC identified at least one sentinel node in 100 of 111 patients (identification rate 90%). In six cases, a false-negative SN was identified, resulting in a false-negative rate of 13% (6 of 47). We only found little correlation between patients and tumor characteristics and the identification rate or false-negative rate. Lymphatic mapping and SNB after primary chemotherapy failed to predict histologic infiltration of the sentinel node with sufficient sensitivity. The routine use of SNB after primary chemotherapy should therefore be discouraged.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EWEwald Woell
Ewald Woell
PRPeter Regitnig
Peter Regitnig
WEWolfgang Eisterer
Wolfgang Eisterer
JTJosef Thaler
Josef Thaler
HOHorst Oexle
Horst Oexle
RGRichard Greil
Richard Greil
E15501 Background: Trastuzumab plus chemotherapy is the treatment of choice for locally advanced or metastatic gastric cancer patients. Pathological assessment of gastric cancer specimens however still remains difficult albeit it is a crucial prerequisite for optimal treatment. Methods: This registry was designed as a prospective, observational, multi-center research initiative comparing HER2 test results obtained from the local pathology department and to reevaluate HER2 testing in a central pathology laboratory. HER2 testing was performed by means of immunohistochemistry (IHC) and in equivocal cases (Score 2+) in addition by in-situ hybridization (ISH).In the central laboratory HER2 IHC was carried out using the HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody. In the local pathologies up to four different kits were used.The rate of HER2 positive locally advanced or metastatic gastric or GEJ cancer is the primary study objective. Comparison of HER2 results from local and central labs, safety, PFS, OS and type of chemoimmunotherapy in HER2 positive patients are additional objectives. Results: Up to now samples of 127 patients have been tested in local and central pathology respectively. Median age was 68 years, median weight 68 kg. 59 patients already had at least one prior treatment for metastatic disease. 20 out of 127 tested samples (15.7%) showed discordance between central and local testing with 6/127 (4.7%) false negative results and 14/127 (11.0%) false positive results. 37 patients (29.0%) tested HER2 positive in local pathology. 30 of which were treated with trastuzumab in combination with different chemotherapy backbones (53.3% first line). Median PFS was 6.5 months, overall survival was 12.0 months. PFS and OS were shorter in patients with false positive results (5.7 and 7.6 months, respectively). Conclusions: This ongoing registry points to the fact that HER2 testing in gastric cancer is difficult, and highlights the necessity for quality insurance to optimize individual treatment options. Although different chemotherapy backbones are used PFS is similar to published data.